<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03838848</url>
  </required_header>
  <id_info>
    <org_study_id>KN046-201</org_study_id>
    <nct_id>NCT03838848</nct_id>
  </id_info>
  <brief_title>KN046 in Patients With Advanced Non-small Cell Lung Cancer</brief_title>
  <official_title>A Phase II Study to Evaluate the Efficacy, Safety, and Tolerability of KN046 in Patients With Advanced Non-small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu Alphamab Biopharmaceuticals Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu Alphamab Biopharmaceuticals Co., Ltd</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase II, open label, multicenter study in subjects with advanced non-small cell
      lung cancer.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 5, 2019</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Cohort A, B and C are carried out in sequence, a Scientific Monitoring Committee (SMC) will decide whether to enter the next group (A to B, B to C).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ORR</measure>
    <time_frame>2 years</time_frame>
    <description>clinical response rate (ORR) as determined by the independent review board (IRC) based on RECIST 1.1 criteria</description>
  </primary_outcome>
  <primary_outcome>
    <measure>DOR</measure>
    <time_frame>2 years</time_frame>
    <description>clinical response time (DOR) as determined by the independent review board (IRC) based on RECIST 1.1 criteria</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">149</enrollment>
  <condition>Stage IV Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Safety cohort KN046 3mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with Non-small Cell Lung Cancer (NSCLC) (failed or did not tolerant to platinum-containing regime and did not treat with programmed cell death protein 1/the programmed death-ligand 1 (PD1/PDL-1) checkpoint inhibitor previously) will receive KN046 3 milligram per kilogram (mg/kg), every other weeks (Q2W)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Safety cohort KN046 5mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with NSCLC (failed or did not tolerant to platinum-containing regime and did not treat with PD1/PDL-1 checkpoint inhibitor previously) will receive KN046 5 mg/kg, Q2W</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Efficacy cohort KN046</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with NSCLC (failed or did not tolerant to platinum-containing regime and failed to PD1/PDL-1 checkpoint inhibitor) will receive KN046</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KN046</intervention_name>
    <description>KN046, Q2W, intravenous injection (IV) for 90-120 minites.</description>
    <arm_group_label>Efficacy cohort KN046</arm_group_label>
    <arm_group_label>Safety cohort KN046 3mg</arm_group_label>
    <arm_group_label>Safety cohort KN046 5mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed inform consent form(ICF)

          2. Age ≥ 18 years and ≤ 75 years, male or female

          3. Histologically or cytologically documented NSCLC, stage IV (M1a or M1b),
             Histologically confirmed epidermal growth factor receptor (EGFR) wild type or
             insensitive mutation.

          4. At least one measurable lesion according to Response Evaluation Criteria In Solid
             Tumors（RECISIT） v 1.1

          5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

          6. Adequate organ function

          7. Female patients and males with partners of childbearing potential should be using
             highly effective contraceptive measures (failure rate of less than 1% per year).
             Contraception should be continued for a period of 24 weeks after dosing has been
             completed.

          8. Ability to comply with treatment, procedures and pharmacokinetics (PK) sample
             collection and the required study follow-up procedures

        Exclusion Criteria:

          1. Known brain metastasis or another Central Nervous System (CNS) metastasis that is
             either symptomatic or untreated.

          2. Is currently participating or has participated in a study of an investigational drug
             within 4 weeks prior to the first dose of trial treatment.

          3. Patients who have received immune checkpoint proteins/antibody/medicine (including
             PD-1, PD-L1, etc.) for treatment.

          4. Has interstitial lung disease, or a history of pneumonitis that required oral or
             intravenous glucocorticoids to assist with management.

          5. Subjects with active autoimmune diseases or history of autoimmune diseases should be
             excluded.

          6. Active Hepatitis B Virus (HBV) or Hepatitis C Virus (HCV) infection.

          7. Known HIV infection or known history of acquired immune deficient syndrome (AIDS).

          8. Any unresolved the Common Terminology Criteria for Adverse Events (CTCAE) Grade ≥ 2
             toxicities from prior anti-cancer therapy except for vitiligo, alopecia.

          9. Patients who have serious hypersensitive reaction to monoclonal antibodies and have
             history of uncontrolled allergic asthma.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Caicun Zhou, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Pulmonary Hospital, Shanghai, China</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yong Gui</last_name>
    <phone>86-21-65115006</phone>
    <email>fkyygcp@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wei Li, MD</last_name>
    <phone>86-21-65115006</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shanghai Pulmonary Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anwen Xiong, PhD</last_name>
      <phone>86-21-65115006</phone>
      <phone_ext>3050</phone_ext>
      <email>anwenxiong@yeah.net</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>February 1, 2019</study_first_submitted>
  <study_first_submitted_qc>February 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 12, 2019</study_first_posted>
  <last_update_submitted>July 7, 2020</last_update_submitted>
  <last_update_submitted_qc>July 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

